CN105796755A - Traditional Chinese medicinal composition for treating diabetic nephropathy - Google Patents
Traditional Chinese medicinal composition for treating diabetic nephropathy Download PDFInfo
- Publication number
- CN105796755A CN105796755A CN201610320909.4A CN201610320909A CN105796755A CN 105796755 A CN105796755 A CN 105796755A CN 201610320909 A CN201610320909 A CN 201610320909A CN 105796755 A CN105796755 A CN 105796755A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- caulis spatholobi
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Abstract
The invention relates to a traditional Chinese medicinal composition for treating diabetic nephropathy, belonging to the technical field of traditional Chinese medicines. The traditional Chinese medicinal composition is prepared from the following medicinal materials: caulis spatholobi, radix astragali, radix salviae miltiorrhizae, fructus crataegi, safflower carthamus, rhizoma coptidis, fructus arctii, the fruits of Chinese wolfberry, cortex cinnamomi and licorice root. According to the traditional Chinese medicinal composition, the medicinal materials are reasonable in composition and strong in synergistic effect, and very obvious treatment effects are achieved on the diabetic nephropathy.
Description
The application be applicant Linyi Cao Zhimei Pharmaceutical Technology Co., Ltd propose application for a patent for invention (denomination of invention is: a kind of Chinese medicine composition for prepare treatment medicine for treating diabetic nephropathy in purposes, application number is: 2015106523252, and the applying date is: on October 10th, 2015) divisional application.
Technical field
The present invention relates to a kind of Chinese medicine composition treating diabetic nephropathy, belong to technical field of Chinese medicines.
Background technology
Diabetic nephropathy is a kind of chronic complicating diseases that serious and hazardness that diabetes cause is maximum, it it is one of diabetes generalized capillary pathological changes performance, Clinical symptoms is albuminuria, gradual renal function injury, hypertension,, there is severe renal nonfunction late period in edema, is one of the major causes of death of diabetics.
Current western medical treatment is many sets about from aspects such as strengthening glycemic control, blood pressure lowering, adjustment lipid metabolism, or adopts the treatment meanss such as dialysis, renal transplantation, although effectively, but bring heavy financial burden to patient.Chinese traditional treatment has rich experience, and effect is obvious, no dependence, and overall dialectical, individuality treats, and makes human internal organ be in harmonious proportion, equilibrium between yin and yang, recovers benign cycle, obtains good therapeutic effect.Additionally Chinese traditional treatment also has safety high, and side effect is little, not easily the advantage such as recurrence.
Chinese patent application 201210311984.6 discloses a kind of Chinese medicine composition for treating diabetic nephropathy, and this Chinese medicine composition is prepared by following raw material: the Radix Astragali, dried lily bulb, Semen Persicae, Hirudo, Radix Et Rhizoma Rhei, Rhizoma Alismatis, Fructus Rosae Laevigatae, Semen Euryales, Radix Achyranthis Bidentatae, the Cortex Eucommiae.This Chinese medicine composition has supplementing QI and nourishing YIN, clearing heat and expelling damp, effect of promoting blood circulation to remove obstruction in the collateral, but this Chinese medicine composition is at blood sugar lowering, and kidney and spleen invigorating aspect effect is not very notable.
Chinese patent application 201310036878.6 discloses a kind of Chinese medicine decoction treating diabetic nephropathy, its crude drug composition includes Rhizoma Pinelliae Preparatum, Pericarpium Citri Reticulatae, the Rhizoma Atractylodis Macrocephalae, Poria, Semen Coicis, Rhizoma Dioscoreae, the Radix Astragali, Radix Rehmanniae Preparata, Fructus Corni, Ramulus Cinnamomi, Radix Glycyrrhizae, Herba Leonuri, Herba Lycopi, Flos Carthami, Radix Salviae Miltiorrhizae, preparation method is for, after being soaked in water, decocting and get final product.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition treating diabetic nephropathy, and this Chinese medicine composition has blood sugar lowering and guarantor's kidney protects the effects such as kidney, also has good effect, the advantages such as side effect is low, taking convenience.Additionally, the present invention also provides for corresponding manufacturing process, this pharmaceutical composition is made and facilitated easy-to-use preparation under the premise ensureing curative effect.
In order to solve above-mentioned technical problem, the technical scheme is that
A kind of Chinese medicine composition treating diabetic nephropathy, prepares raw material including following parts by weight: Caulis Spatholobi 10-15 part, Radix Astragali 6-20 part, Radix Salviae Miltiorrhizae 9-15 part, Fructus Crataegi 3-10 part, Flos Carthami 3-10 part, Rhizoma Coptidis 3-10 part, Fructus Arctii 6-15 part, Fructus Lycii 6-15 part, Cortex Cinnamomi 3-10 part and Radix Glycyrrhizae 6-15 part.
Preferably, what described Chinese medicine composition included following parts by weight prepares raw material: Caulis Spatholobi 10 parts, the Radix Astragali 15 parts, Radix Salviae Miltiorrhizae 9 parts, Fructus Crataegi 10 parts, 10 parts of Flos Carthami, Rhizoma Coptidis 5 parts, Fructus Arctii 6 parts, Fructus Lycii 15 parts, Cortex Cinnamomi 10 parts and 15 parts of Radix Glycyrrhizae.
Preferably, what described Chinese medicine composition included following parts by weight prepares raw material: Caulis Spatholobi 15 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 12 parts, Fructus Crataegi 3 parts, 6 parts of Flos Carthami, Rhizoma Coptidis 3 parts, Fructus Arctii 15 parts, Fructus Lycii 10 parts, Cortex Cinnamomi 3 parts and 6 parts of Radix Glycyrrhizae.
Preferably, what described Chinese medicine composition included following parts by weight prepares raw material: Caulis Spatholobi 12 parts, the Radix Astragali 6 parts, Radix Salviae Miltiorrhizae 15 parts, Fructus Crataegi 6 parts, 3 parts of Flos Carthami, Rhizoma Coptidis 8 parts, Fructus Arctii 10 parts, Fructus Lycii 6 parts, Cortex Cinnamomi 6 parts and 10 parts of Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made into capsule, tablet, powder, granule or pill.
Accordingly, the preparation method of described Chinese medicine composition comprises the steps:
A) Caulis Spatholobi is weighed, pulverize, adding medical material weight 2-5 times amount volume fraction is the alcoholic solution of 60-90%, add the cellulase of medical material weight 0.8%-1.5%, lixiviate 1-3 hour at 38-45 DEG C, then 85-95 DEG C reflux, extract, 1-2 hour, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution；
B) Radix Astragali, Radix Salviae Miltiorrhizae, Fructus Crataegi, Flos Carthami, Rhizoma Coptidis, Fructus Arctii, Fructus Lycii, Cortex Cinnamomi and Radix Glycyrrhizae are weighed, add described Caulis Spatholobi filtering residue, pulverize, add the water soaking of 3-8 times of weight after 1-3 hour, boil 1-5 hour, filter, obtain filtrate, in filtering residue, add the alcoholic solution that volume fraction is 60-90% of 2-5 times of weight, boil 1-3 hour, filter, obtain filtrate, merge twice filtrate；
C) by described Caulis Spatholobi extracting solution and described twice filtrate mixing, it is concentrated into the thick paste that relative density is 1.15-1.25, drying under reduced pressure, crosses 100-200 mesh sieve after pulverizing, obtain Chinese medicine composition.
The source of component used by the present invention, nature and flavor, return through and effect:
Caulis Spatholobi: this product is the dry rattan of leguminous plant spatholobus suberectus；Bitter in the mouth, sweet, warm in nature；Return liver, kidney channel；Enrich blood, invigorate blood circulation, dredging collateral.
The Radix Astragali: for the root of the leguminous plant Radix Astragali；Sweet in the mouth, tepor；Return lung, spleen, liver, kidney channel；Invigorating QI to consolidate the body surface resistance, expelling pus and toxin by strengthening QI, diuresis, granulation promoting.
Radix Salviae Miltiorrhizae: for the dry root and rhizome of labiate Radix Salviae Miltiorrhizae；Bitter in the mouth, cold nature；GUIXIN, Liver Channel；Stasis-dispelling and pain-killing, promoting blood circulation to restore menstrual flow, clear away heart-fire relieving restlessness.
Fructus Crataegi: containing compositions such as multiple organic acid, vitamin Cs, being administered orally can appetite stimulator；Gastrointestinal motility function is had adjustment effect by Fructus Crataegi, the gastrointestinal smooth muscle of spasticity there is is inhibitory action, the smooth muscle of relaxed state is had excitation, in addition, Fructus Crataegi flavone, hydrolyzate increase ischemic myocardium nutrient flow amount, wherein the strongest with Fructus Crataegi hydrolyzate effect.Fructus Crataegi is while increasing coronary artery blood flow, moreover it is possible to reduce myocardial oxygen consumption, improves coefficient of oxygen utilization.
Flos Carthami: belong to feverfew, has the effect of good promoting blood circulation to restore menstrual flow network, eliminating stasis to stop pain, and the traditional Chinese medical science thinks that Flos Carthami nature and flavor are gentle, and myocardial ischemia has a lot of benefit, and also having a function is exactly can expansion body coronary arteries and femoral artery.The spasm of vascular smooth muscle can also be released and strengthen hypoxia-bearing capability, stoping the further development of thrombosis, reduce again the effect of cholesterol.Can also improving the circulatory disturbance of heart and brain tissues, the treatment for coronary heart disease and cerebral thrombosis is beneficial to.
Rhizoma Coptidis: for the dry rhizome of ranunculaceae plant Rhizoma Coptidis；Bitter in the mouth, cold in nature；GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel；Heat clearing and damp drying, eliminating fire and detoxication.
Fructus Arctii: acrid in the mouth, warm in nature；Expelling wind and cold pain relieving.
Fructus Lycii: for the dry mature fruit of plant of Solanaceae lycium barbarum；Sweet in the mouth, property is put down；Return liver, kidney channel；Nourishing the liver and kidney, replenishing vital essence to improve eyesight.
Cortex Cinnamomi: for the dry bark of canella Cortex Cinnamomi；Acrid in the mouth, sweet, extremely hot in nature；Return kidney, spleen, the heart, Liver Channel；Mend fire supporing yang, let the fire back to its origin, dispersing cold for relieving pain, promoting blood circulation to restore menstrual flow.
Radix Glycyrrhizae: for the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L..Sweet in the mouth, property is put down；GUIXIN, lung, spleen, stomach warp；Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
Compared with prior art, there is advantages that
1, Chinese medicine composition of the present invention have employed the medical materials such as Caulis Spatholobi, the Radix Astragali and Radix Salviae Miltiorrhizae, by the synergism of each composition activity composition, it is achieved that the therapeutic effect to diabetic nephropathy；
2, compared with the chemicals of Current therapeutic diabetic nephropathy, described Chinese medicine composition is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, and described Chinese medicine composition effect is comprehensive, medication effect is more preferably, significantly improve the compliance of diabetics, and improve the quality of life of patient.
3, Chinese medicine composition of the present invention has the effects such as guarantor's kidney protects that kidney, blood sugar lowering and spleen invigorating are invigorated blood circulation, and also has good effect, the advantages such as cost is low, and obvious effective rate is high, taking convenience.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following example represents the technology playing good action in the practice of the invention that the inventors discovered that.But, disclosed specific embodiments can be made many changes, and still obtain same or analogous result, without deviating from the spirit and scope of the present invention.
Embodiment 1
What Chinese medicine composition of the present invention included following parts by weight prepares raw material: Caulis Spatholobi 10 parts, the Radix Astragali 15 parts, Radix Salviae Miltiorrhizae 9 parts, Fructus Crataegi 10 parts, 10 parts of Flos Carthami, Rhizoma Coptidis 5 parts, Fructus Arctii 6 parts, Fructus Lycii 15 parts, Cortex Cinnamomi 10 parts and 15 parts of Radix Glycyrrhizae.
Preparation method is as follows: weigh Caulis Spatholobi, pulverizes, and adding medical material weight 4 times amount volume fraction is the alcoholic solution of 75%, adding the cellulase of medical material weight 1%, lixiviate 2 hours at 42 DEG C, then 90 DEG C of reflux, extract, 2 hours, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution；Weigh the Radix Astragali, Radix Salviae Miltiorrhizae, Fructus Crataegi, Flos Carthami, Rhizoma Coptidis, Fructus Arctii, Fructus Lycii, Cortex Cinnamomi and Radix Glycyrrhizae, add described Caulis Spatholobi filtering residue, pulverize, add the water soaking of 4 times of weight after 2 hours, boil 3 hours, filter, obtain filtrate, in filtering residue, add the alcoholic solution that volume fraction is 75% of 2 times of weight, boil 2 hours, filter, obtain filtrate, merge twice filtrate；By described Caulis Spatholobi extracting solution and described twice filtrate mixing, it is concentrated into the thick paste that relative density is 1.20, drying under reduced pressure, crosses 200 mesh sieves after pulverizing, obtain Chinese medicine composition, add the conventional adjuvant of capsule, load in capsule shells, obtain Chinese medicinal composition capsules agent.
Embodiment 2
What Chinese medicine composition of the present invention included following parts by weight prepares raw material: Caulis Spatholobi 15 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 12 parts, Fructus Crataegi 3 parts, 6 parts of Flos Carthami, Rhizoma Coptidis 3 parts, Fructus Arctii 15 parts, Fructus Lycii 10 parts, Cortex Cinnamomi 3 parts and 6 parts of Radix Glycyrrhizae.
Preparation method is as follows: weigh Caulis Spatholobi, pulverizes, and adding medical material weight 5 times amount volume fraction is the alcoholic solution of 70%, adding the cellulase of medical material weight 0.8%, lixiviate 2 hours at 40 DEG C, then 85 DEG C of reflux, extract, 2 hours, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution；Weigh the Radix Astragali, Radix Salviae Miltiorrhizae, Fructus Crataegi, Flos Carthami, Rhizoma Coptidis, Fructus Arctii, Fructus Lycii, Cortex Cinnamomi and Radix Glycyrrhizae, add described Caulis Spatholobi filtering residue, pulverize, add the water soaking of 6 times of weight after 2 hours, boil 3 hours, filter, obtain filtrate, in filtering residue, add the alcoholic solution that volume fraction is 70% of 3 times of weight, boil 2 hours, filter, obtain filtrate, merge twice filtrate；By described Caulis Spatholobi extracting solution and described twice filtrate mixing, it is concentrated into the thick paste that relative density is 1.25, drying under reduced pressure, crosses 200 mesh sieves after pulverizing, obtain Chinese medicine composition, add the conventional adjuvant of capsule, load in capsule shells, obtain Chinese medicinal composition capsules agent.
Embodiment 3
What Chinese medicine composition of the present invention included following parts by weight prepares raw material: Caulis Spatholobi 12 parts, the Radix Astragali 6 parts, Radix Salviae Miltiorrhizae 15 parts, Fructus Crataegi 6 parts, 3 parts of Flos Carthami, Rhizoma Coptidis 8 parts, Fructus Arctii 10 parts, Fructus Lycii 6 parts, Cortex Cinnamomi 6 parts and 10 parts of Radix Glycyrrhizae.
Preparation method is as follows: weigh Caulis Spatholobi, pulverizes, and adding medical material weight 2 times amount volume fraction is the alcoholic solution of 75%, adding the cellulase of medical material weight 1.5%, lixiviate 2 hours at 42 DEG C, then 90 DEG C of reflux, extract, 2 hours, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution；Weigh the Radix Astragali, Radix Salviae Miltiorrhizae, Fructus Crataegi, Flos Carthami, Rhizoma Coptidis, Fructus Arctii, Fructus Lycii, Cortex Cinnamomi and Radix Glycyrrhizae, add described Caulis Spatholobi filtering residue, pulverize, add the water soaking of 6 times of weight after 2 hours, boil 3 hours, filter, obtain filtrate, in filtering residue, add the alcoholic solution that volume fraction is 75% of 2 times of weight, boil 2 hours, filter, obtain filtrate, merge twice filtrate；By described Caulis Spatholobi extracting solution and described twice filtrate mixing, it is concentrated into the thick paste that relative density is 1.15, drying under reduced pressure, crosses 200 mesh sieves after pulverizing, obtain Chinese medicine composition, add the conventional adjuvant of capsule, load in capsule shells, obtain Chinese medicinal composition capsules agent.
The Chinese medicine composition of the present invention therapeutical effect to Diabetic nephropathy animal model
1, model is prepared
Select healthy male adult SD rats 40, body weight 0.35kg-0.4kg, feed with high lipid food, do not limit and take the photograph water.Abdominal cavity is injected with streptozotocin after rat is carried out unilateral kidney ligation operation.Operation consent Rat Fast 12h, injection Nembutal sodium solution is anaesthetized, after confirming anesthesia, by rat along kidney base of a fruit ligation kidney arteriovenous and ureter.When postoperative 2 weeks, each group Rat Fast 18h, then disposable celiac injects 1% streptozotocin solution 0.55g/kg, and concrete administration volume is 5.5ml/kg, and after injection, rat freely ingests water.After modeling completes 72h, survey blood glucose through tail vein blood.Modeling Success criteria: 1. fasting glucose >=16.65mmol/L；2. glucose in urine strong positive；3. urine volume is more than the 50% of matched group, i.e. modeling success.
2, experiment packet and administration
After modeling terminates, 40 rats are randomly divided into 4 groups, often group 10, respectively model group, pioglitazone group, Chinese medicine A group and Chinese medicine B group.Each group gives following medicine respectively:
Model group: the isopyknic distilled water of gavage；
Pioglitazone group: gavage pioglitazone 0.25g/kg d；
Chinese medicine A group: the Chinese medicinal composition capsules agent 0.3g/kg d of the gavage embodiment of the present invention 1 preparation；
Chinese medicine B group: the Chinese medicinal composition capsules agent 0.3g/kg d of the gavage embodiment of the present invention 2 preparation；
Above-mentioned each group every day gastric infusion once, continuous 8 weeks, normally raise.Blood sampling measures fasting glucose and microdose urine protein.
3, index determining
(1) mensuration of blood glucose: all rats take tail vein detection fasting glucose before administration and after being administered 8 weeks, the blood sample of taking-up is put in protein precipitant, after room temperature places 7min, centrifugal 5min(3000r/min), take supernatant, use determination of glucose oxidase blood glucose value.
(2) mensuration of microalbumin in urine: rat after being administered 8 weeks is put in metabolic cage respectively and raises, collect 12 hours overnight urine, accurate recording urine volume.Take 4ml, after sodium azide processes, centrifugal (2000r/min) 10min, take supernatant and be placed in-20 DEG C of refrigerators and preserve urinaryalbumin to be measured.The albumin standards 400ml taking respective concentration adds in supernatant, is separately added into 200ml0.231mmol/L bromophenol blue developer, mixing, with ultraviolet spectrophotometer, measures OD value under 600nm wavelength.
4, experimental result and discussion
The Chinese medicine composition that table 1 the present invention relates to impact on diabetic nephropathy rats fasting glucose
Note: compare with model group, * P < 0.05, * * P < 0.01；
As shown in Table 1, after Chinese medicine A and B group administration, the blood glucose value of rat substantially reduces, and compared with model group, has the difference (P < 0.01) of significance, and wherein, the change of blood sugar value of Chinese medicine B group is maximum；The blood glucose value of Chinese medicine A and B group is better than pioglitazone group, but no difference of science of statistics；Visible, the Chinese medicine composition that the present invention relates to can significantly reduce the blood glucose of diabetic nephropathy rats, and the Chinese medicine composition that the present invention relates to can be used for treating diabetic nephropathy.
The Chinese medicine composition that table 2 the present invention relates to impact on diabetic nephropathy rats microdose urine protein
Note: compare with model group, * P < 0.05, * * P < 0.01.
As shown in Table 3, compared with model group, the microdose urine protein content of pioglitazone group and Chinese medicine A, B group all has significant difference (P < 0.01).Visible, Chinese medicine composition of the present invention has good synergism in treatment diabetic nephropathy rats microdose urine protein, its therapeutic effect is better than pioglitazone group, but no difference of science of statistics, this shows that the Chinese medicine composition that the present invention relates to has prominent treatment advantage in delaying diabetic nephropathy PD.
The Chinese medicine composition of the present invention observation of curative effect to diabetic nephropathy clinical patients volunteer
One, diagnostic criteria
Tcm diagnosis standard: have foam in urine, weak, nausea and vomiting, shallow complexion or dark and gloomy, heavy sensation of the body edema, soreness of the waist and knees and abdominal distention, nocturia, forgetful, insomnia, dizziness and tinnitus, feverish sensation in the palms and soles, purplish tongue or light red tongue or ecchymosis, thick fur is greasy, deep-thready pulse or puckery；Dialectical lose for weakness of the spleen and kidney, lung logical adjust, the water stasis of blood is tied mutually, water turbid regardless of.
Two, evaluation of clinical curative effect standard
Effective: clinical symptoms is improved substantially, soreness of the waist and knees, fatigue and weak, dry mouth and throat, nocturia etc. disappear or substantially disappear, and blood sugar level fluctuated within normal range, blood pressure≤128/80mmHg, 24h urine protein < 30mg, blood urea nitrogen and creatinine are all down to normal level；
Effective: clinical symptom relief, soreness of the waist and knees, fatigue and weak, dry mouth and throat, nocturia etc. be improved significantly, fasting glucose control ideal, fluctuation of blood pressure all has decline at about 140/90mmHg, 24h urine protein and blood urea nitrogen creatinine, but does not take a turn for the better completely；
Invalid: clinical symptoms is improved inconspicuous, blood pressure and blood glucose are without declining or having decline but undesirable, and 24h urine protein quantitation and blood urea nitrogen creatinine all do not decline, or decline not up to effective standard.
Three, clinical trial
1, physical data
All selected diabetic nephropathy clinical volunteers patients are randomly divided into 3 groups, treat A group 50 example, treat B group 50 example, matched group 50 example.Age is 40 years old-60 years old, the influence factor such as 3 groups of ages, sex, symptoms, through statistical procedures, there was no significant difference, meets packet condition.
2, Therapeutic Method
Treatment A group: take the capsule that embodiment 1 prepares, every day 3 times, each 4, serve on 1 month；
Treatment B group: take the capsule that embodiment 2 prepares, every day 3 times, each 4, serve on 1 month；
Matched group: take TANGMAIKANG KELI (quasi-word Z10970026, the 5g*10 bag/box of traditional Chinese medicines), one time 1 bag, 3 times on the one, serve on 1 month.
3, therapeutic outcome
Table 3 therapeutic effect
This test adopts TANGMAIKANG KELI as a control group, TANGMAIKANG KELI has replenishing YIN and removing heat, blood circulation promoting and blood stasis dispelling, QI invigorating is reinforced the kidney, hypoglycemic effect, can be used for treating the patient such as non-insulin-dependent diabetes mellitus and complication, by comparing with traditional Chinese medicine composition for treating effect of the present invention, embodying the Chinese medicine composition of the present invention curative effect in the sick nephropathy for the treatment of urine, the obvious effective rate for the treatment of A group and treatment B group is all higher than 80%, total effective rate is all higher than 85%, is better than obvious effective rate and the total effective rate of matched group.Visible, pharmaceutical composition good effect of the present invention, obvious effective rate is high, it is possible to as the drug use for the treatment of diabetic nephropathy.
Owing to describing the present invention already by above preferred embodiment, in the spirit and/or scope of the present invention, the present invention is implemented in any replacement/for the present invention or combination, will be apparent from for a person skilled in the art, and is included among the present invention.
Claims (6)
1. the Chinese medicine composition treating diabetic nephropathy, it is characterised in that what include following parts by weight prepares raw material: Caulis Spatholobi 10-15 part, Radix Astragali 6-20 part, Radix Salviae Miltiorrhizae 9-15 part, Fructus Crataegi 3-10 part, Flos Carthami 3-10 part, Rhizoma Coptidis 3-10 part, Fructus Arctii 6-15 part, Fructus Lycii 6-15 part, Cortex Cinnamomi 3-10 part and Radix Glycyrrhizae 6-15 part.
2. the Chinese medicine composition treating diabetic nephropathy as claimed in claim 1, it is characterised in that what include following parts by weight prepares raw material: Caulis Spatholobi 10 parts, the Radix Astragali 15 parts, Radix Salviae Miltiorrhizae 9 parts, Fructus Crataegi 10 parts, 10 parts of Flos Carthami, Rhizoma Coptidis 5 parts, Fructus Arctii 6 parts, Fructus Lycii 15 parts, Cortex Cinnamomi 10 parts and 15 parts of Radix Glycyrrhizae.
3. the Chinese medicine composition treating diabetic nephropathy as claimed in claim 1, it is characterised in that what include following parts by weight prepares raw material: Caulis Spatholobi 15 parts, the Radix Astragali 10 parts, Radix Salviae Miltiorrhizae 12 parts, Fructus Crataegi 3 parts, 6 parts of Flos Carthami, Rhizoma Coptidis 3 parts, Fructus Arctii 15 parts, Fructus Lycii 10 parts, Cortex Cinnamomi 3 parts and 6 parts of Radix Glycyrrhizae.
4. the Chinese medicine composition treating diabetic nephropathy as claimed in claim 1, it is characterised in that what include following parts by weight prepares raw material: Caulis Spatholobi 12 parts, the Radix Astragali 6 parts, Radix Salviae Miltiorrhizae 15 parts, Fructus Crataegi 6 parts, 3 parts of Flos Carthami, Rhizoma Coptidis 8 parts, Fructus Arctii 10 parts, Fructus Lycii 6 parts, Cortex Cinnamomi 6 parts and 10 parts of Radix Glycyrrhizae.
5. the Chinese medicine composition of the treatment diabetic nephropathy as described in as arbitrary in claim 1-4, it is characterised in that: described Chinese medicine composition is made into capsule, tablet, powder, granule or pill.
6. the Chinese medicine composition of the treatment diabetic nephropathy as described in as arbitrary in claim 1-4, it is characterised in that described Chinese medicine composition prepares by the following method:
(1) Caulis Spatholobi is weighed, pulverize, adding medical material weight 2-5 times amount volume fraction is the alcoholic solution of 60-90%, add the cellulase of medical material weight 0.8%-1.5%, lixiviate 1-3 hour at 38-45 DEG C, then 85-95 DEG C reflux, extract, 1-2 hour, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution；
(2) Radix Astragali, Radix Salviae Miltiorrhizae, Fructus Crataegi, Flos Carthami, Rhizoma Coptidis, Fructus Arctii, Fructus Lycii, Cortex Cinnamomi and Radix Glycyrrhizae are weighed, add described Caulis Spatholobi filtering residue, pulverize, add the water soaking of 3-8 times of weight after 1-3 hour, boil 1-5 hour, filter, obtain filtrate, in filtering residue, add the alcoholic solution that volume fraction is 60-90% of 2-5 times of weight, boil 1-3 hour, filter, obtain filtrate, merge twice filtrate；
(3) by described Caulis Spatholobi extracting solution and described twice filtrate mixing, it is concentrated into the thick paste that relative density is 1.15-1.25, drying under reduced pressure, crosses 100-200 mesh sieve after pulverizing, obtain Chinese medicine composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610320909.4A CN105796755A (en) | 2015-10-10 | 2015-10-10 | Traditional Chinese medicinal composition for treating diabetic nephropathy |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510652325.2A CN105168581A (en) | 2015-10-10 | 2015-10-10 | Application of traditional Chinese medicine composition in preparation of drugs for treating diabetic nephropathies |
| CN201610320909.4A CN105796755A (en) | 2015-10-10 | 2015-10-10 | Traditional Chinese medicinal composition for treating diabetic nephropathy |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510652325.2A Division CN105168581A (en) | 2015-10-10 | 2015-10-10 | Application of traditional Chinese medicine composition in preparation of drugs for treating diabetic nephropathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105796755A true CN105796755A (en) | 2016-07-27 |
Family
ID=54891336
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610320909.4A Withdrawn CN105796755A (en) | 2015-10-10 | 2015-10-10 | Traditional Chinese medicinal composition for treating diabetic nephropathy |
| CN201510652325.2A Withdrawn CN105168581A (en) | 2015-10-10 | 2015-10-10 | Application of traditional Chinese medicine composition in preparation of drugs for treating diabetic nephropathies |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510652325.2A Withdrawn CN105168581A (en) | 2015-10-10 | 2015-10-10 | Application of traditional Chinese medicine composition in preparation of drugs for treating diabetic nephropathies |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105796755A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375254A (en) * | 2017-08-30 | 2017-11-24 | 李炜 | A kind of external plaster and its application method for being used to treat diabetes |
| CN111567729A (en) * | 2020-05-22 | 2020-08-25 | 北京曜食同源商贸有限公司 | Health food for preventing and treating diabetic nephropathy and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940596A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
| CN104940531A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Application of Chinese herbal composition to preparation of medicine for treating diabetic nephropathy |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102614405B (en) * | 2012-04-06 | 2015-03-11 | 刘英晓 | Traditional Chinese medicine decoction for curing limb pain caused by diabetic neuropathy |
| CN102836329B (en) * | 2012-08-29 | 2014-11-26 | 张定华 | Chinese medicinal composition for treating diabetic nephropathy |
| CN104958536A (en) * | 2015-07-29 | 2015-10-07 | 青岛蓝盛洋医药生物科技有限责任公司 | Chinese medicinal composition for treating diabetes and preparation method thereof |
-
2015
- 2015-10-10 CN CN201610320909.4A patent/CN105796755A/en not_active Withdrawn
- 2015-10-10 CN CN201510652325.2A patent/CN105168581A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104940596A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Traditional Chinese medicine composition for treating diabetic nephropathy and preparation method thereof |
| CN104940531A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Application of Chinese herbal composition to preparation of medicine for treating diabetic nephropathy |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107375254A (en) * | 2017-08-30 | 2017-11-24 | 李炜 | A kind of external plaster and its application method for being used to treat diabetes |
| CN111567729A (en) * | 2020-05-22 | 2020-08-25 | 北京曜食同源商贸有限公司 | Health food for preventing and treating diabetic nephropathy and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105168581A (en) | 2015-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988750B (en) | TCM (Traditional Chinese medicine) composition for treating diabetes and preparation method thereof | |
| CN102302563B (en) | Chinese medicinal composition for treating chronic kidney failure and preparation method thereof | |
| CN104940531A (en) | Application of Chinese herbal composition to preparation of medicine for treating diabetic nephropathy | |
| CN101428113A (en) | Traditional Chinese medicine preparation for treating type II diabetes and preparation method thereof | |
| CN103690784B (en) | The Chinese medicine composition for the treatment of Complicating with Hypentersion nephropathy and preparation method | |
| CN107789484A (en) | A kind of Chinese medicine composition for treating irregular menstruation and preparation method thereof | |
| CN101095768B (en) | Chinese traditional medicine capsule for treating primary hypertension for persons in middle and old age | |
| CN103301356A (en) | Preparation method of enema for chronic renal failure | |
| CN104083640A (en) | Traditional Chinese medicinal composition for treating diabetes mellitus and preparation method thereof | |
| CN103301355A (en) | Preparation method of chronic renal failure colon dialysate | |
| CN105796755A (en) | Traditional Chinese medicinal composition for treating diabetic nephropathy | |
| CN101095798B (en) | Chinese traditional medicine for treating canities | |
| CN103705860B (en) | A kind of Chinese medicine composition for the treatment of infant jaundice and preparation method thereof | |
| CN105343593A (en) | Spica prunellae health oral liquid capable of decreasing blood pressure and blood lipid as well as preparation method of spica prunellae health oral liquid | |
| CN103751558B (en) | A kind of compound antihypelipidemic pill and preparation method thereof | |
| CN105311470A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating diabetic nephropathy | |
| CN1192789C (en) | 'Shenhuaxiaokecha' tea and preparing method thereof | |
| CN100398123C (en) | Medicine for treating diabetes of blood stasis complicated kidney spleen deficiency type | |
| CN105213777A (en) | A kind of Chinese medicine composition is for the preparation of the purposes in treatment medicine for treating diabetic nephropathy | |
| CN104096073A (en) | Traditional Chinese medicine composition for treating male infertility and preparation method for same | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104189615B (en) | Traditional Chinese medicine preparation for treating metrorrhagia and metrostaxis, and preparation method of traditional Chinese medicine preparation | |
| CN108853340A (en) | A kind of Chinese medicine of nourishing the liver and kidney and preparation method thereof | |
| CN103341095A (en) | Clysis liquid used for chronic renal failure | |
| CN102526358B (en) | Medicinal composition for treating diabetes and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160727 |
|
| WW01 | Invention patent application withdrawn after publication |